ATE507211T1 - Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer - Google Patents

Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer

Info

Publication number
ATE507211T1
ATE507211T1 AT07757668T AT07757668T ATE507211T1 AT E507211 T1 ATE507211 T1 AT E507211T1 AT 07757668 T AT07757668 T AT 07757668T AT 07757668 T AT07757668 T AT 07757668T AT E507211 T1 ATE507211 T1 AT E507211T1
Authority
AT
Austria
Prior art keywords
beta
hydroxysteroid dehydrogenase
inhibitors
triazine
dehydrogenase type
Prior art date
Application number
AT07757668T
Other languages
English (en)
Inventor
Jun Li
Jeffrey A Robl
Lawrence J Kennedy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE507211T1 publication Critical patent/ATE507211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT07757668T 2006-03-01 2007-03-01 Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer ATE507211T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77815906P 2006-03-01 2006-03-01
US11/679,898 US7834178B2 (en) 2006-03-01 2007-02-28 Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PCT/US2007/063012 WO2007103694A2 (en) 2006-03-01 2007-03-01 Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors

Publications (1)

Publication Number Publication Date
ATE507211T1 true ATE507211T1 (de) 2011-05-15

Family

ID=38375689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757668T ATE507211T1 (de) 2006-03-01 2007-03-01 Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer

Country Status (5)

Country Link
US (1) US7834178B2 (de)
EP (1) EP1989190B1 (de)
AT (1) ATE507211T1 (de)
DE (1) DE602007014186D1 (de)
WO (1) WO2007103694A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
EP3337497B1 (de) 2015-08-21 2023-07-12 SRX Cardio, LLC Zusammensetzung und verfahren zur verwendung von neuartigen kleinen organischen phenylalaninverbindungen zur direkten modulation der pcsk9-proteinaktivität
EP3337564A4 (de) 2015-08-21 2019-01-23 Portola Pharmaceuticals, Inc. Zusammensetzung und verfahren zur verwendung von tetrahydroisochinolin-kleinmolekülen zur bindung und modulation der pcsk9-proteinaktivität
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CN112272666A (zh) * 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
CN110746429B (zh) * 2018-12-10 2022-11-25 广州华睿光电材料有限公司 含金刚烷的化合物、高聚物、混合物、组合物及电子器件
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (de) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. Verfahren und zusammensetzungen zur modulierung der spleissung
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
CU20210080A7 (es) 2019-04-02 2022-05-11 Array Biopharma Inc Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
AU2020291468A1 (en) * 2019-06-14 2022-01-06 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
EP4611743A1 (de) * 2022-11-02 2025-09-10 Merck Sharp & Dohme LLC Triazine als inhibitoren des nod-ähnlichen rezeptorproteins 3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836531A (en) * 1969-12-11 1974-09-17 Asahi Chemical Ind Synthetic nacreous pigments and method for production thereof
BE786840A (fr) * 1971-07-29 1973-01-29 Bayer Ag Procede de preparation de 1,2,4-triazine -5-ones
DE2802488A1 (de) * 1978-01-20 1979-07-26 Bayer Ag 3-azolyl-benzotriazine und -benzotriazin-1-oxide, verfahren zu ihrer herstellung, sowie ihre verwendung zur bekaempfung von pflanzenkrankheiten
EP0186868A3 (en) 1985-01-02 1988-09-21 Eastman Kodak Company Photographic element and process for providing metal complex color images
US4701420A (en) 1985-04-01 1987-10-20 Eastman Kodak Company Analytical compositions, elements and methods utilizing reduction of ferric ion chelates to form detectable dyes
US5616584A (en) * 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5069708A (en) * 1989-07-14 1991-12-03 Basf Aktiengesellschaft Pyrimido(5,4-e)-as-triazine-5,7(6H,8H)-diones
CA2041800C (en) 1990-07-31 2003-04-29 Claudia C. Pierce On-line iron (ii) concentration monitoring to continuously determine corrosion in boiler systems
US5110347A (en) * 1990-11-26 1992-05-05 E. I Du Pont De Nemours And Company Substituted fused heterocyclic herbicides
JPH0551369A (ja) * 1991-05-21 1993-03-02 Sumitomo Chem Co Ltd ６−置換−３，５−ジフエニル−１，２，４−トリアジン誘導体、それを有効成分とする除草剤およびその製造中間体
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5827850A (en) * 1995-09-25 1998-10-27 Sanofi Pharmaceuticals, Inc. 1,2,4-benzotriazine oxides formulations
CO5210943A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de triazina, composiciones para el control de plagas que comprenden dicho compuesto y cuando menos un auxiliar y metodos para controlar plagas
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1397351T3 (da) * 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
DE60332433D1 (de) * 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
US6846928B2 (en) * 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7304061B2 (en) * 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004007499A1 (en) * 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003286876A1 (en) * 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2006071644A1 (en) * 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
ATE451363T1 (de) * 2005-01-26 2009-12-15 Schering Corp 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
CN101528713B (zh) 2005-07-05 2013-05-22 霍夫曼-拉罗奇有限公司 作为11β-羟基类固醇脱氢酶1型抑制剂的哒嗪衍生物
WO2007038452A1 (en) 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
CA2623728A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
US7981910B2 (en) 2005-10-20 2011-07-19 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1

Also Published As

Publication number Publication date
EP1989190A2 (de) 2008-11-12
WO2007103694A2 (en) 2007-09-13
DE602007014186D1 (de) 2011-06-09
EP1989190B1 (de) 2011-04-27
US7834178B2 (en) 2010-11-16
US20070207985A1 (en) 2007-09-06
WO2007103694A3 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
ATE507211T1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
TW200716116A (en) Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2006113261A3 (en) Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
EA200900344A1 (ru) Циклические ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
EA200900821A1 (ru) Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
EA200700220A1 (ru) Имидазотриазины в качестве ингибиторов протеинкиназы
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MX338557B (es) Compuesto heterociclico y uso del mismo.
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
PL1771178T3 (pl) Zastosowanie K-252A i inhibitorów kinazy do zapobiegania lub leczenia patologii związanych z HMGB1
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
DK1981851T3 (da) Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2011041304A3 (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties